Clinical Trials
19 trialsReal-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Peking University People's Hospital
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
Tianjin Medical University Cancer Institute and Hospital
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
Peking University Cancer Hospital & Institute
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HER2-DM-NACT
Hebei Medical University Fourth Hospital
CCGLC-018
Tongji Hospital
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pyrotinib in HER2-positive Early Breast Cancer
Yunnan Cancer Hospital
SPRING
Peking University Shenzhen Hospital
Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
Henan Cancer Hospital
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Xi'an International Medical Center Hospital
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Shengjing Hospital
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University